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Case R eport: Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient
Coinfected with L eishmania braziliensis and Its E ndosymbiotic Virus
Laurent Parmentier,† A lexia Cusini,† Norbert Müller, Haroun Z angger, Mary-A nne H artley, Chantal D esponds,
Patrik Castiglioni, Patrick D ubach, Catherine R onet, Stephen M. Beverley, and Nicolas Fasel*
Department of D ermatology, University Hospital of Bern, Bern, Switzerland; Department of Infectious Diseases, University Hospital of Bern, Bern,
Switzerland; Institute of P arasitology, Vetsuisse Faculty Berne, University of Bern, Bern, Switzerland; Department of Biochemistry, University
of L ausanne, L ausanne, Switzerland; Department of E ar, Neck and Throat, Head and Neck Surgery, University Hospital of Bern,
Bern, Switzerland; Department of Molecular Microbiology, Washington University School of Medicine, St. L ouis, Missouri

Abstract. L eishmania parasites cause a broad range of disease, with cutaneous afflictions being, by far, the most
prevalent. Variations in disease severity and symptomatic spectrum are mostly associated to parasite species. O ne risk
factor for the severity and emergence of leishmaniasis is immunosuppression, usually arising by coinfection of the
patient with human immunodeficiency virus (H IV). Interestingly, several species of L eishmania have been shown to
bear an endogenous cytoplasmic dsR NA virus (LRV) of the Totiviridae family, and recently we correlated the presence
of LRV1 within L eishmania parasites to an exacerbation murine leishmaniasis and with an elevated frequency of drug
treatment failures in humans. This raises the possibility of further exacerbation of leishmaniasis in the presence of both
viruses, and here we report a case of cutaneous leishmaniasis caused by L eishmania braziliensis bearing LRV1 with
aggressive pathogenesis in an H IV patient. LRV1 was isolated and partially sequenced from skin and nasal lesions.
Genetic identity of both sequences reinforced the assumption that nasal parasites originate from primary skin lesions.
Surprisingly, combined antiretroviral therapy did not impact the devolution of L eishmania infection. The L eishmania
infection was successfully treated through administration of liposomal amphotericin B.

INTR OD U CTION

parasite. In this case report, we recount the clinical presentation, diagnosis, and successful treatment of this severe
cutaneous leishmaniasis in an H IV-positive patient caused by
L . braziliensis and its cytoplasmic virus.

L eishmania parasites infect over 2 million people annually
and cause a broad range of disease, with cutaneous afflictions being, by far, the most prevalent.1 Variations in disease
severity and symptomatic spectrum are mostly associated with
parasite species. This is reflected by the geographical distribution of severely disseminated (D L) and mucosal leishmaniases (ML), which occur predominantly in Central and South
A merica and E thiopia. L eishmania braziliensis, L eishmania
panamensis, L eishmania guyanensis, and L eishmania aethiopica are the main causative species of these aggressive
forms of leishmaniasis, which progress from a primary cutaneous lesion in 5–10% of infected patients.2,3
L eishmania braziliensis, L . guyanensis, and L . aethiopica
species are known to be variously infected by L eishmania
R NA virus (LRV), a cytoplasmic double-stranded R NA
(dsR NA ) virus of the Totiviridae family.2,4,5 LRV presence is
predominant in the A mazonian basin.6 Previously, we showed
that this virus (LRV1) within the L . guyanensis parasites
exacerbates disease outcome in a murine model by inducing
a hyperinflammatory response with increased interferon β,7
and inflammatory markers commonly found in the lesions of
ML patients.8,9 R ecently, we and collaborators showed that
the presence of LRV1 in L . guyanensis and L . braziliensis is
a risk factor for relapse in drug-treated patients.10,11
Leishmaniasis is a rising opportunistic complication in human
immunodeficiency virus (HIV)–positive individuals.12 Although
it is well known that the parasite can take advantage of the
concomitant acquired immunodeficiency syndrome (A ID S)–
related immunosuppression, potentially this could be further
exacerbated by the presence of LRV1 within the infecting

CA SE R E PO RT
The patient, a 60-year-old female, presented at the clinic
with several skin ulcerations on the limbs and trunk. The
patient had been living in Paraguay for the three previous
years and her lesions first developed 9 months earlier during
a 1-month stay in Bolivia, where she was treated empirically
for bacterial ecthyma. A concomitant H IV test was found positive after which she decided to travel back to Switzerland
for further medical management. The initial physical examination revealed several large, ovoid skin ulcerations, ranging
from 5 to 15 cm in diameter, with raised erythematic borders
and a clear exudate (Figure 1A and B). The patient was
apyretic and had no additional complaints.
Combined antiretroviral therapy (cA RT) with tenofovir,
emtricitabine, and efavirenz was initiated based on a high
viremia of 1,764 copies/mL (CD 4-cell count of 803 cells/μL)
and on the presence of a coinfecting L eishmania parasite.
Treatment decreased viremia to 482 copies/mL after 2 months.
The patient’s skin lesions, however, continued to slowly
progress, at which point she was referred to the dermatology
department for further evaluation.
In addition to the skin lesions, the patient complained
of a recently acquired unilateral rhinitis and nasal congestion. A nasal endoscopy revealed unilateral focal granulomatous hyperplasia of the head of the middle turbinate
(Figure 1C). Magnetic resonance imaging showed no cartilaginous destruction or paranasal involvement. ML was suspected. Touch preparations from skin exudates disclosed no
L eishmania amastigotes, and biopsies from lesion borders
and nasal granulomatous tissue revealed chronic nonspecific
inflammation, with no L eishmania, fungal, or mycobacterial
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F IG UR E 1. Cutaneous and mucosal metastatic leishmaniasis caused by L eishmania RNA virus–laden L eishmania braziliensis in a human
immunodeficiency virus–coinfected patient. Pre-therapeutic examination (A –C) finds large well-demarcated skin ulcerations of the axillary
regions and posterior trunk (A and B) while a nasal endoscopy (C) reveals granulomatous inflammation of the nasal mucosa on the head of the
middle turbinate. One month after A mBisome treatment, skin lesions healed completely with mild discoloration and scarring (D and E). Nasal
lesions resolved 3 months later after an additional round of A mBisome therapy (F).

organisms (by Giemsa, periodic acid–Schiff, and Ziehl–Neelsen
stains, respectively).
O n admission, a blood sample and two intralesional biopsies were isolated from the patient: one from a cutaneous
lesion and the other from a metastatic lesion in the nasal
mucosa. Two standard leishmanial diagnostic procedures
(in vitro cultivation and polymerase chain reaction [PCR ])
were undertaken on each of the three isolates. L eishmania
parasites could be expanded from both cutaneous and nasal
mucosa specimens, albeit absent in blood samples. PCR
amplified a standard leishmanial diagnostic marker (internal
transcribed spacer 1 of L eishmania small subunit ribosomal
R NA ).13 Direct sequencing of the amplified products was
obtained and comparative sequence analysis of the diagnostic PCR products was done by applying the nucleotide
BLA ST ® algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi)
(GeneBank ™ sequence database; accession no. JN936955).
The alignment of the PCR products categorized both parasite isolates as L . braziliensis. Isolates were thereafter assigned
World Health Organization format identifiers MHO M/BO /
2011/2169 (L b2169, skin lesion) and MH O M/BO /2011/2192
(L b2192, nasal lesion).
Considering that our patient had a severely disseminated
form of cutaneous leishmaniasis and an inflamed nasal mucosa,
we determined that the L. braziliensis parasites from these
lesions were infected by LRV1.14 We completed our study by
obtaining pure LRV1 dsR NA after reverse transcription into
complementary D NA (cDNA ), performing PCR amplification using 10 primers (information available at: http://people
.unil.ch/nicolasfasel/supptab1_lbhiv/) and sequencing 4,969 bp
of this dsR NA (G enBank accession no. KC862308). Its
structure paralleled the open reading frames of previously
sequenced LRV1 isolated from L . guyanensis parasites (data
not shown). A n LRV1-specific PCR of parasite cD NA preparations from isolated viral dsR NA of both isolates was
sequenced, confirming LRV1 presence in both isolates. The

genetic identity of LRV1 between both isolates supports the
assumption that mucosal parasites had migrated from primary skin lesions.
A lthough the standard first-line treatment of ML relies on
pentavalent antimony (sodium stibogluconate or meglumine
antimoniate),15,16 we opted for a second-line therapy with
liposomal amphotericin B,17 whose efficacy and tolerance
profiles are favorable in D L as well as in H IV-coinfected
patients and for treatment of antimony-resistant strains.18
O ur choice was motivated by the evolution and severity of
the disease, where numerous, large diameter (up to 15 cm)
skin lesions had evolved and persisted for over 10 months,
together with the potentially disfiguring involvement of the
nasal mucosa.
The patient received intravenous liposomal amphotericin B
for five successive days at 3 mg/kg (150 mg per infusion) with
two additional infusions at days 14 and 21 (cumulative dose:
21 mg/kg, i.e., 1,050 mg). The cutaneous lesions of the limbs
and trunk began to heal 2 weeks after treatment initiation and
were completely re-epithelialized after 1 month (Figure 1D
and E). The nasal mucosa required additional liposomal amphotericin infusions (cumulative dose: 27 mg/kg, i.e., 1,350 mg) to
achieve complete healing with no residual deformation of the
nasal structure (Figure 1F). Six months posttreatment, the
patient had no infectious relapse and displayed only mild
discoloration of the healed wounds.
D ISCU SSION
This study was the first account of a patient coinfected
with H IV and a strain of L . braziliensis carrying the cytoplasmic dsR NA virus, LRV1. The patient presented with a
particularly exacerbated form of cutaneous leishmaniasis,
with individual metastatic skin lesions measuring up to 15 cm
in diameter as well as a further parasitic infestation in the
nasal mucosa. A lthough D L may present with ulcers and/
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or mucosal involvement, even in H IV-negative patients,19–21
this patient’s symptomology was distinct from that of
L . braziliensis D L 21 and from H IV/L . braziliensis coinfections because of the number of large ulcerated disseminated
lesions.22 A lthough exacerbations of leishmaniasis are common in HIV coinfection due to a collapse of the CD4 T-cell
compartment, the patient described here had a low CD4-cell
count at the start of cA RT. Further, cA RT had no effect on
disease progression, contrary to visceral leishmaniasis/HIV
coinfection, where restoration of the CD4-cell count usually
results in a significant amelioration of disease. Q uite oppositely, the patient condition did not improve clinically with
progressing cutaneous lesions.
The presence of L eishmania along with two viruses (one
internal, one external) could underlie this severe form of
disease, and may potentially explain some of the unusual
manifestations of A merican tegumentary leishmaniasis caused
by L . braziliensis or L . guyanensis reported in H IV-positive
patients,23,24 which are especially frequent in regions of South
A merica where LRV1 is known to be most prevalent, such
as French G uyana and the Brazilian A mazon.25,26 Indeed,
H IV and LRV dsR NA may synergize to worsen leishmaniasis, where H IV coinfection not only increases the incidence
of L eishmania infection, but also the patient’s risk of developing metastatic or chronic complications of leishmaniasis.
The retrospective nature of this report and the lack of epidemiological data did not allow us to definitively ascertain
the joint detrimental roles of LRV1 and HIV in human leishmanial disease progression. H owever, we can hypothesize
that the clinical presentation reported here of LRV1-carrying
Leishmania infection is in line with what is observed in relapses
in L . braziliensis- and L . guyanensis-infected patients and in
experimental animal models and could explain some of the
unusual manifestations of A merican tegumentary leishmaniasis reported in H IV-positive patients,23,24,27 as well as the
commonly observed treatment failures and relapses.10–12,26
U sing PCR conditions and primers described in this study, a
large-scale screen for LRV1 as a risk factor in leishmaniasis
patients will be instrumental to unlocking the potential of
exploiting this nested viral infection for use as a diagnostic
and prognostic marker.
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